Loading clinical trials...

To Evaluate the Bioavailability of a Tablet of AZD1656 | Clinical Trials | Clareo Health

COMPLETEDPHASE1

To Evaluate the Bioavailability of a Tablet of AZD1656

A Randomized, Open, Single-Dose, Single-Centre, Cross-over, Phase I Study in Type 1 Diabetes Mellitus Patients to Estimate the Extent and Rate of Absorption of AZD1656 After Administration of a Tablet Formulation in the Fasting State and Just Before Food in Comparison With an Oral Suspension of AZD1

NCT00817505•AstraZeneca

View on ClinicalTrials.gov

Summary

To evaluate the bioavailability of a tablet of AZD1656.

Eligibility

Age

20 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female, type I diabetes patients, female with non child-bearing potential.
•Treated with insulin for more than 3 years. Well controlled HbA1c.
•Have a body mass index (BMI) ≥19 and ≤35

Exclusion Criteria

•Clinically significant illness except type I diabetes, or clinically relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the investigational product
•Daily use of nicotine containing substances.

Locations (1)

Research site

San Antonio, Texas, United States

Key Dates

Start Date

December 1, 2008

Primary Completion Date

March 1, 2009

Completion Date

September 1, 2009

Last Updated

November 3, 2009

Enrollment

ACTUAL participants

Conditions

Type 1 Diabetes

Interventions

AZD1656

DRUG

AZD1656

DRUG

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGNA

Aerobic vs Resistance Exercise in Post-menopausal Women With Type 1 Diabetes

NCT05188027

Type 1 DiabetesPost-menopause

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 3, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

To Evaluate the Bioavailability of a Tablet of AZD1656

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Aerobic vs Resistance Exercise in Post-menopausal Women With Type 1 Diabetes

Dysautonomia in Children With Type 1 Diabetes

Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes

Lipoprotein Kinetics in T1D

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery